Neurocrine Biosciences Inc

$95.60
(as of Apr 4, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Neurocrine Biosciences Inc

Stock Price
$95.60
Ticker Symbol
NBIX
Exchange
NASDAQ

Industry Information for Neurocrine Biosciences Inc

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Neurocrine Biosciences Inc

Country
USA
Full Time Employees
1,800

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Fundamentals for Neurocrine Biosciences Inc

Market Capitalization
$10,257,496,064
EBITDA
$610,099,968
Dividends per Share
P/E Ratio
31.27
Forward P/E Ratio
21.79
Earnings per Share
$3.29
Earnings per Share Estimate Next Year
Profit Margin
14.49%
Shares Outstanding
99,703,504
Percent Owned by Insiders
1.02%
Percent Owned by Institutions
98.07%
52-Week High
52-Week Low

Technical Indicators for Neurocrine Biosciences Inc

50-Day Moving Average
200-Day Moving Average
RSI
23.58
3.79

Analyst Ratings for Neurocrine Biosciences Inc

Strong Buy
15
Buy
5
Hold
4
Sell
0
Strong Sell
0

News About Neurocrine Biosciences Inc

Apr 4, 2025, 8:00 AM EST
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas See more.
Mar 31, 2025, 8:30 AM EST
All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six Months Findings Presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting See more.
Mar 25, 2025, 7:08 AM EST
Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. See more.
Mar 20, 2025, 8:30 AM EST
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference See more.